|
Novo Nordisk
|
 29/01/2010
[Company watch]
Novo Nordisk Awaits China Approval of Type 2 Diabetes Treatment
Novo Nordisk reported that Victoza®, its once-daily human glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes, was submitted to the SFDA in August of last year.
|
| |
|
ChinaBio Today -- Novo Nordisk reported that Victoza®, its once-daily human glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes, was submitted to the SFDA in August of last year. The news came as Novo Nordisk celebrated approval of the product in the US and Japan this week. It has been marketed in Europe since last summer. |
|
|
|
|
